

The American Journal of Human Genetics, Volume 98

Supplemental Data

Somatic Activating Mutations in *GNAQ* and *GNA11*

Are Associated with Congenital Hemangioma

Ugur M. Ayturk, Javier A. Couto, Steven Hann, John B. Mulliken, Kaitlin L. Williams, August Yue Huang, Steven J. Fishman, Theonia K. Boyd, Harry P.W. Kozakewich, Joyce Bischoff, Arin K. Greene, and Matthew L. Warman




Figure S1: The number of genes with variants as a function of the number of samples in which they were detected. Four hundred and three genes with at least one variant were detected in at least one sample. Using our initial filtering criteria, *GNAQ* variants were detected in 3 samples, whereas a *GNA11* variant was detected in only 1 sample.




Figure S2: Somatic mutations in genes that are associated with congenital vascular tumors and malformations in humans. Mutations in genes encoding several different protein components of MAP kinase and mTOR signaling pathways have been identified in affected tissue from individuals with a vascular tumor or malformation. Relative locations and connections between different components in the signaling pathways are indicated by grey lines (arrowheads indicate a component that normally increases signaling and bars indicate a component that normally inhibits signaling). Colored text indicates the specific disorders and colored arrows point to pathway component(s) that can be responsible for causing the disorder¹⁻¹⁸. A condition for which a germline mutation may also be causal is indicated with an asterisk.




Figure S3: Fraction of the protein coding sequence covered by RNA-seq and representative whole exome data as a function of read depth. Whole exome datasets (derived from non-hemangioma tissue, unpublished) are generated with 33-42 million reads, making them comparable to the RNA-seq datasets generated with 32-47 million reads per library.

Gene Symbol	Chr	Pos	Ref/Var	Evaluation Notes
<i>ATN1</i>	12	7045882	G/T	Likely misalignment: Variants are present in a region with highly repeated sequence. The reads can map to the same region with a 6bp in-frame deletion and without mismatches.
		7045885	A/C	
		7045888	G/T	
		7045891	A/C	
		7045894	G/C	
		7045924	G/T	
<i>B3GNT2</i>	2	62449455	G/A	Likely sequencing error: The variant is in the middle of a repeated A sequence. Several other reads indicate single base-pair deletions/insertions (A).
<i>GNAQ</i>	9	80409487	T/G	No visible evidence of mismapping or sequencing errors. The altered codon is highly conserved.
		80409488	T/A	
<i>IL13RA1</i>	X	117892031	G/A	Likely sequencing error: The variant is in the middle of a repeated A sequence. Several other reads indicate single base-pair insertions (A).
<i>NBPF11</i>	1	146052732	G/C	Possible misalignment: The reads could be mapped to other positions with better scores.
		146057326	A/T	
		146057343	C/A	
		147579272	A/G	
<i>PLEKHO1</i>	1	150131221	G/A	Likely sequencing error: The variant is at the end of a repeated A sequence. Several other reads indicate single base-pair insertions (A).
<i>SMC4</i>	3	160131304	G/A	Likely sequencing error: The variant is in the middle of a repeated A sequence. Several other reads indicate single base-pair deletions/insertions (A).
		160134135	G/A	
<i>SSC5D</i>	19	56029182	A/C	Potential sequencing/mapping error: The variants are present in repetitive GC-rich regions at low level, and are accompanied by several other mismatches.
		56029484	C/G	
		56029524	A/C	
		56030202	C/A	
<i>TBX3</i>	12	115115392	C/T	Likely sequencing error: The variant is at the end of a repeated T sequence. Several other reads indicate single base-pair insertions (T).
<i>TCF7L2</i>	10	114925316	G/A	Likely sequencing error: The variant is at the end of a repeated A sequence. Several other reads indicate single base-pair insertions (A).
<i>TCHP</i>	12	110344434	G/A	Likely sequencing error: The variant is in the middle of a repeated A sequence. Several other reads indicate single base-pair insertions (A).
<i>POLR2J2/UPK3BL</i>	7	102280786	T/G	Possible misalignment: The reads could be mapped to other positions with similar scores.

Table S1: The variants identified in 12 genes by filtering RNA-seq data from 8 participants.

Primer Sequences

GNAQ fwd:5'-TTCCCTAAGTTTGTAAGTAGTGCT-3'; rev:5'-TCCATTGCCTGTCTAAAGAACAC-3'

GNA11 fwd: 5'-CAGCCGATGTCAGTCTGGT-3'; rev: 5'-GGCGACGAGAAACATGATGGA-3'

Probe Sequences

GNAQ Reference: 5'-/5HEX/CTTCTCTCTGACCTTTGGCCCCCTA/3IABkFQ/-3';

GNA11 Reference: 5'-/5HEX/CGCTCCGACCGCTGGCC/3IABkFQ/-3'

GNAQ.c626A>T: 5'-/56-FAM/TCTCTCTGACCTT**A**GGCCCCCTAC/3IABkFQ/-3'

GNAQ.c626A>C: 5'-/56-FAM/TCTCTCTGACCTT**G**GGCCCCCTAC/3IABkFQ/-3'

GNA11.c626A>T: 5'-/56-FAM/ACCGC**A**GGCCCCCACA/3IABkFQ/-3'

Table S2: Sequences of primers and probes used in the ddPCR assays.

<u>Probe ID</u>	<u>MIP sequence</u>
<i>GNAQ_1</i>	GTCACTGTCTGGGTTCCAGGTCCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGGGCGGGTGTCTAGGAGG
<i>GNAQ_2</i>	CGGCCAAGAGACAAGAGGGGACACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGCAAAGACAAAGCGGATA
<i>GNAQ_3</i>	GTTCTAAAGAGAGCCTTGCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGCTGTGGTATGAGTGCTGACT
<i>GNAQ_4</i>	ACCCCTGGTTCCAGAACTCCTCGGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGATGGGTTGGACTTAT
<i>GNAQ_5</i>	GCCCCCTACATCGACCATTCTGCACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNTCCATTGCCTGTCTAA
<i>GNAQ_6</i>	TGACGATGATCATCCAAGTCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNTTTCTTCTCTCTGACCTTG
<i>GNAQ_7</i>	CAGGGTCAGCTACGCGGTCCAAGTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNAGGCATAAAAGCTGGG
<i>GNAQ_8</i>	GCTTAGAGTTCCAGTCCCCACCACCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNTTTTTGTCCTTCCCTT
<i>GNAQ_9</i>	CAGGTGGCCCTATGGATTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGTTGATGTGGAGAAGGTGTCTG
<i>GNAQ_10</i>	CCTGGAATCCAGGAATGCTATGATCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNTGGAAAGTAATAGGGT
<i>GNAQ_11</i>	GCGACTCTTCATTGGAGCAGTCAGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGGGTCAGGATACTCTG
<i>GNAQ_12</i>	CAGAACATCTTCACGGCCATGCAGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGTGGTCTGATGAGCTG
<i>GNAQ_13</i>	GTGAGTACCGTCCGGGGCCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNTGGAAGAATGACTCTGGAGTC
<i>GNAQ_14</i>	GATCGAGCGGCAGCTCCGCAGGGACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGGAGGGTGTGTGTGCG
<i>GNA11_1</i>	GCGAGCTCAAGCTGCTGCTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNAGGCGCCGCGTCGGCCGGGG
<i>GNA11_2</i>	ACTCCAGAGTCATCGTCCCGGCCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGGGGGCCGCACTCACCGA
<i>GNA11_3</i>	GCACGTGAGGGCGGGCGGCAGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNTGCATGGCGGTGAAGATGT
<i>GNA11_4</i>	GCTTGGTGGTGAGCATGGTGGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNAAGCTCGTCTACCAGAACA
<i>GNA11_5</i>	CGTGGATGATGCGCATCTGCTTGACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNCTCACCTTGTCTGCT
<i>GNA11_6</i>	CCCTGTGGGAGGACCCGGGCATCCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNTTCTGGTGGATGTGTGG
<i>GNA11_7</i>	TAAGTGCGGCCGCACCGCTGGCGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGGGAGGTGGACGTGGAG
<i>GNA11_8</i>	GCTGCAACACAGCGGTGGGTGCTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGGGCGGTACCGGAAGAT
<i>GNA11_9</i>	CGCCTGAGTCCAGGAGTTTGAGACCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNTTCGACCTGGAGAACA
<i>GNA11_10</i>	GACGGAAGCCACCAGGAGGGGGTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNTGCTGGGTGGGCAGGT
<i>GNA11_11</i>	GTGGAGTCGGACAACGAGGTGGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNTGAGTCTGGCGCTGTGT
<i>GNA11_12</i>	TGCCCTGAGCAGGGGCAGCGTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGGATGGTGGATGTGGGGGG
<i>GNA11_13</i>	GCTGATATGGGAGAGGGGCTCATACTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNCTTCTCAACAAGAAG
<i>GNA11_14</i>	GCGAAGGCAGAGGGAATCAGAGGGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGGTGCGAGTACAGGAT
<i>GNA11_15</i>	GGAGGGCAGAGGGTGAAGGCTGTCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNAACACGAAGCGGATGTTC
<i>GNA11_16</i>	GCAGCTCAACCTCAAGGAGTACCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGGCGGCGGGAGTTCAT
<i>GNA11_17</i>	CGGTGGCACACGTGAAGTGTGAGCTTCAGCTTCCCGATATCCGACGGTAGTGTNNNNNNNGTGAAGGAAGGTCTCTG

Table S3: Sequences of probes used in the MIP-seq assays.

Supplemental Data References

1. Couto, J.A., Huang, L., Vivero, M.P., Kamitaki, N., Maclellan, R.A., Mulliken, J.B., Bischoff, J., Warman, M.L., and Greene, A.K. (2015). Endothelial Cells from Capillary Malformations are Enriched for Somatic GNAQ Mutations. *Plast Reconstr Surg*.
2. Nakashima, M., Miyajima, M., Sugano, H., Iimura, Y., Kato, M., Tsurusaki, Y., Miyake, N., Saitsu, H., Arai, H., and Matsumoto, N. (2014). The somatic GNAQ mutation c.548G>A (p.R183Q) is consistently found in Sturge-Weber syndrome. *J Hum Genet* 59, 691-693.
3. Shirley, M.D., Tang, H., Gallione, C.J., Baugher, J.D., Frelin, L.P., Cohen, B., North, P.E., Marchuk, D.A., Comi, A.M., and Pevsner, J. (2013). Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. *N Engl J Med* 368, 1971-1979.
4. Eerola, I., Boon, L.M., Mulliken, J.B., Burrows, P.E., Domp Martin, A., Watanabe, S., Vanwijck, R., and Vikkula, M. (2003). Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. *Am J Hum Genet* 73, 1240-1249.
5. Groesser, L., Peterhof, E., Evert, M., Landthaler, M., Berneburg, M., and Hafner, C. (2015). BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma. *J Invest Dermatol*.
6. Lim, Y.H., Douglas, S.R., Ko, C.J., Antaya, R.J., McNiff, J.M., Zhou, J., Choate, K.A., and Narayan, D. (2015). Somatic Activating RAS Mutations Cause Vascular Tumors Including Pyogenic Granuloma. *J Invest Dermatol* 135, 1698-1700.
7. Liaw, D., Marsh, D.J., Li, J., Dahia, P.L., Wang, S.I., Zheng, Z., Bose, S., Call, K.M., Tsou, H.C., Peacocke, M., et al. (1997). Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. *Nat Genet* 16, 64-67.
8. Couto, J.A., Vivero, M.P., Kozakewich, H.P., Taghinia, A.H., Mulliken, J.B., Warman, M.L., and Greene, A.K. (2015). A somatic MAP3K3 mutation is associated with verrucous venous malformation. *Am J Hum Genet* 96, 480-486.
9. Limaye, N., Kangas, J., Mendola, A., Godfraind, C., Schlogel, M.J., Helaers, R., Eklund, L., Boon, L.M., and Vikkula, M. (2015). Somatic Activating PIK3CA Mutations Cause Venous Malformation. *Am J Hum Genet* 97, 914-921.
10. Vikkula, M., Boon, L.M., Carraway, K.L., 3rd, Calvert, J.T., Diamonti, A.J., Goumnerov, B., Pasyk, K.A., Marchuk, D.A., Warman, M.L., Cantley, L.C., et al. (1996). Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. *Cell* 87, 1181-1190.
11. Kurek, K.C., Luks, V.L., Ayturk, U.M., Alomari, A.I., Fishman, S.J., Spencer, S.A., Mulliken, J.B., Bowen, M.E., Yamamoto, G.L., Kozakewich, H.P., et al. (2012). Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. *Am J Hum Genet* 90, 1108-1115.
12. Boscolo, E., Coma, S., Luks, V.L., Greene, A.K., Klagsbrun, M., Warman, M.L., and Bischoff, J. (2015). AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation. *Angiogenesis* 18, 151-162.
13. Osborn, A.J., Dickie, P., Neilson, D.E., Glaser, K., Lynch, K.A., Gupta, A., and Dickie, B.H. (2015). Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations. *Hum Mol Genet* 24, 926-938.
14. Riviere, J.B., Mirzaa, G.M., O'Roak, B.J., Beddaoui, M., Alcantara, D., Conway, R.L., St-Onge, J., Schwartzentruber, J.A., Gripp, K.W., Nikkel, S.M., et al. (2012). De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. *Nat Genet* 44, 934-940.
15. Lindhurst, M.J., Sapp, J.C., Teer, J.K., Johnston, J.J., Finn, E.M., Peters, K., Turner, J., Cannons, J.L., Bick, D., Blakemore, L., et al. (2011). A mosaic activating mutation in AKT1 associated with the Proteus syndrome. *N Engl J Med* 365, 611-619.
16. Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O'Brien, J.M., Simpson, E.M., Barsh, G.S., and Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. *Nature* 457, 599-602.

17. Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B., Garrido, M.C., Vemula, S., Wiesner, T., Obenaus, A.C., Wackernagel, W., Green, G., Bouvier, N., et al. (2010). Mutations in GNA11 in uveal melanoma. *N Engl J Med* 363, 2191-2199.
18. Maat, W., Kilic, E., Luyten, G.P., de Klein, A., Jager, M.J., Gruis, N.A., and Van der Velden, P.A. (2008). Pyrophosphorolysis detects B-RAF mutations in primary uveal melanoma. *Invest Ophthalmol Vis Sci* 49, 23-27.